brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
gavreto
roche registration gmbh - pralsetinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
bovalto
boehringer ingelheim animal health nordics - bovint respiratorisk syncytialvirus, inaktivert / bovint parainfluensavirus 3, helt, inaktivert / mannheimia haemolytica, serotype a1 stamme dsm 5283, inaktivert - injeksjonsvæske, suspensjon
melatonin agb 5 mg
agb-pharma ab - melatonin - tablett - 5 mg
melatonin agb 1 mg
agb-pharma ab - melatonin - tablett - 1 mg
melatonin agb 2 mg
agb-pharma ab - melatonin - tablett - 2 mg
melatonin agb 3 mg
agb-pharma ab - melatonin - tablett - 3 mg
melatonin agb 4 mg
agb-pharma ab - melatonin - tablett - 4 mg
renvela 800 mg
orifarm as - sevelamerkarbonat - tablett, filmdrasjert - 800 mg
dutasteride/tamsulosin orion 0.5 mg / 0.4 mg
orion corporation - espoo - dutasterid / tamsulosinhydroklorid - kapsel, hard - 0.5 mg / 0.4 mg